Insight Lifetech Completes D+ Round Financing to Continue Leading in Precision Cardiovascular Intervention Solutions

VCBeat (WeChat: vcbeat) has learned thatInsight Lifetech Co., Ltd.: Pioneer in Precision Cardiovascular Interventional Solutions(“InSight Lifetech”) recently completed its Series D+ equity financing. The round was led by existing investor Sherpa Partners, with participation from Taiping Medical Health Fund, QinZhi Capital, Zhouji Tongli under Far East Horizon, and the National Innovation Center. Existing shareholder Sequoia China continued to increase its investment. China Renaissance served as the exclusive financial advisor for this financing round, marking another successful facilitation of efficient capital raising for the company after assisting InSight Lifetech in completing its Series D financing led by Boyu Capital in June 2021. The proceeds from this round will be used to accelerate the market promotion of the company’s multiple product lines, expand production capacity, and advance and strengthen the research and development of innovative product pipelines.

As a national high-tech enterprise providing innovative solutions for precise cardiovascular interventions, InSight Lifetech has approximately 20 products or products under development with global patents, and has efficiently achieved the commercialization of one-stop solutions for complex and precise PCI. Its various products possess internationally leading advantages in terms of innovation and advancement.

Independently developed by InSight Lifetech“Fractional Flow Reserve (FFR) Measurement System”It is the first domestically produced “gold standard” FFR approved by the National Medical Products Administration (NMPA), bringing about a transformation in clinical practice for precise surgical decision-making, and has been highly commended by the NMPA.“Internationally leading, a domestic first; filling the gap in China’s fractional flow reserve (FFR) measurement technology, the gold standard.”; The system received CE marking and NMPA Class III medical device registration approval in March and September 2020, respectively, and has been commercialized in Europe and China.

Independently Developed by InSight Lifetech"Intravascular Ultrasound (IVUS) System"It is China’s first independently innovated 60 MHz high-speed IVUS product, featuring the highest imaging resolution in the industry and the fastest imaging speed globally. Its innovative nature has earned support from the Ministry of Science and Technology’s National Key R&D Program under the “Special Project for R&D of Digital Diagnostic and Therapeutic Equipment.” The system’s performance has been highly acclaimed by leading domestic experts, who noted that “the 60 MHz image resolution surpasses that of other similar products” and that “the 10 mm/s pullback speed enables faster, higher-definition, and more efficient guidance and assessment of stent implantation.” The system has obtained the NMPA Class III Medical Device Registration Certificate and is currently undergoing hospital admission processes across various regions.

InSight Lifetech’s FFR and IVUS systems have both receivedThe qualification for the Special Review Procedure for Innovative Medical Devices has broken the reliance on imported products in this field, making InSight Lifetech the first and only domestic medical technology company to possess a combined portfolio of intravascular functional and imaging products.Helping physicians achieve precise guidance for PCI procedures.

Furthermore, InSight Lifetech’s independently developedCoronary Microcatheter Product PortfolioDesigned for the treatment of complex coronary artery disease, this product features an innovative design and ultimate performance, benchmarking against the highest international standards. Its excellent crossability and ease of clinical operation have been highly acclaimed by leading key opinion leaders (KOLs) in the field of complex lesions in China. It provides clinicians with a device offering superior crossability, maneuverability, and pushability during the treatment of complex coronary artery disease. The product received its National Medical Products Administration (NMPA) Class III medical device registration certificate in April 2022 and is currently in the stage of rapid clinical adoption.

By virtue ofWith the comprehensive market launch of Insight’s PCI product solutions, InSight Lifetech, guided by clinical value and market demand, actively carries out academic promotion activities and provides professional clinical support.Promote the widespread adoption of precision coronary intervention solutions; simultaneously select and cultivate high-quality distributors to establish a global distributor network. The products have entered nearly 1,000 hospitals in China and achieved commercialization and sales in more than 10 developed overseas countries and regions, including Belgium and Germany, with commercial launches in additional countries and regions currently under negotiation.

Adhering to"The Mission of 'Improving Life and Health with Innovation and Quality'", InSight Lifetech has also proactively established a presence in the fields of atrial fibrillation ablation therapy, calcified lesion treatment, and peripheral vascular intervention. The company has developed innovative technologies and product solutions, including Pulsed Field Ablation (PFA) systems and Intravascular Lithotripsy (IVL) balloon catheter systems, demonstrating robust capabilities for sustained expansion.

InSight Lifetech has assembled a team of over 500 experienced mid-career and young professionals from the medical device industry, both domestically and internationally;Established internationally leading R&D platforms for micro-nano devices, interventional catheters, and high-performance medical electronic hardware and software, achieving breakthroughs in multiple “chokehold” technologies., the R&D team covers the innovation and product realization system for three categories of high-performance, high-barrier interventional medical devices, encompassing R&D, clinical trials, regulatory registration, and quality management; it holds over 100 core patents and has more than 200 patent applications in China and overseas; and it has established advanced production lines for active interventional medical devices that meet international quality standards, achieving efficient process optimization and continuous breakthroughs in production capacity and yield rates.

Guided by its original aspiration to create clinical value and its vision of “becoming a world-class medical technology enterprise with lasting impact,” InSight Lifetech has achieved integrated management across the entire R&D, manufacturing, and sales chain, streamlined its value chain, built a highly self-driven learning organization, and fostered an organizational culture and mechanism rich in innovative vitality.InSight Lifetech will launch more innovative products and services that push the boundaries of addressing genuine clinical needs, leading the way in precision interventional cardiovascular solutions and driving transformation in the precise diagnosis and treatment of cardiovascular diseases.

Dr. Song Liang, Founder and Chairman of InSight Lifetech“Improving life and health through innovation and quality is the unwavering mission of InSight Lifetech. We believe that, whether facing a complex international landscape or the severe challenges of the pandemic, our commitment to doing the right thing, persisting in innovative iteration, and staying true to our original aspiration of value creation remains unshaken. We will continue to deepen our engagement in the highly dynamic field of cardiovascular medical devices, remain dedicated to fully meeting genuine clinical and market needs, proactively and efficiently develop and launch technical solutions that best address these needs, and stay true to our original aspiration while forging ahead.”

Mr. Xing Cheng, Partner at Sherpa Investment Managementstated: “Over the years of our collaboration with InSight Lifetech, we have had the opportunity to closely observe how the team has efficiently evolved from its startup beginnings into today’s platform-based company, boasting a robust and comprehensive system for product R&D, manufacturing, and international commercialization. We have been deeply impressed by the team’s forward-looking perspective in R&D, highly innovative product design, and efficient execution. Addressing unmet needs in the diagnosis and treatment within cardiology, InSight Lifetech has developed an innovative portfolio combining active and passive medical devices, establishing initial competitiveness and influence on a global scale. Under the leadership of Dr. Song Liang, the InSight Lifetech team exemplifies the vitality and pioneering spirit of the new generation of Chinese entrepreneurs in the innovative medical device sector, standing out as a distinguished representative of China’s innovative medical device industry in the new era.”

Ms. Lu Shanshan, Deputy General Manager of Taiping InnovationIt stated: “Guided by clinical value and market demand, InSight Lifetech focuses on precision cardiovascular intervention to deliver the most valuable product innovations and solutions. The company possesses the capability to continuously provide high-performance, innovative cardiovascular medical devices and professional services—crafted through ‘Intelligent Manufacturing in China’ and matching the highest international standards—to physicians and patients worldwide. It is an outstanding enterprise that aligns with national strategic priorities, has achieved breakthroughs in key core technologies, and truly demonstrates the capacity for domestic substitution of high-end medical devices. As one of the key builders of Taiping Insurance Group’s ‘Insurance + Medical, Health, and Elderly Care’ ecosystem, the Taiping Medical Health Fund remains committed to advancing the development of precision medicine in China. As a leader in precision cardiovascular intervention solutions, InSight Lifetech looks forward to future collaborative opportunities with Taiping in areas such as ‘Insurance + Precision Medicine.’”

Dr. Tang Dajie, Chairman of QinZhi CapitalIt stated: “InSight Lifetech is a medical technology company providing precision treatment solutions for cardiovascular diseases. It possesses both domestically produced FFR and IVUS systems, making it the only Chinese medical device manufacturer with a portfolio of precision intravascular physiological and imaging products. The InSight FFR system is the first gold-standard FFR approved by China’s National Medical Products Administration (NMPA). It serves as the clinical gold standard for guiding PCI in the diagnosis of myocardial ischemia and has been commercialized in Europe and China. The company’s products feature high technological barriers and a sophisticated, complex supply chain, holding promise to fill the industrial gap in China’s high-end active interventional medical devices sector.”

Mr. Peng Haowei, Co-Managing Director at Zhou Ji Tong LiIt stated: “The core mission of products and services in the healthcare industry is to create value for patients. InSight Lifetech focuses on precise and complex PCI solutions, effectively improving treatment outcomes and reducing the incidence of complications, thereby contributing to industry iteration and benefiting patient health. The InSight Lifetech team has made a strong impression with its courage in tackling technical challenges, profound understanding of the industry, and keen business acumen. The company is one of the few domestic medical device manufacturers capable of outperforming foreign competitors in terms of performance within specific niche categories, demonstrating the potential to become a leader in the active interventional industry and a provider of ‘one-stop’ platform-based solutions.”

Dr. Liu Heng, Deputy General Manager of the National Center for Innovation in High-Performance Medical Devices and General Manager of Guochuang Zhiyuan“He stated, ‘The R&D breakthroughs and successful commercialization of multiple innovative cardiovascular products by InSight Lifetech represent an encouraging and exemplary case in the development of China’s high-end medical device industry. Under the leadership of Dr. Song Liang, the InSight team not only embodies the pioneering spirit, innovation-to-commercialization capability, and resilience in refining high-quality products over many years characteristic of outstanding scientists and engineers, but also demonstrates the mature management expertise, comprehensive system-building capabilities, and efficient market expansion skills of seasoned entrepreneurs. Cultivating and supporting outstanding innovative medical device enterprises is a core mission of the National Innovation Center. The National Innovation Center is honored to participate in this financing round for InSight Lifetech and looks forward to leveraging its rich industrial ecosystem resources to help InSight Lifetech achieve new milestone breakthroughs in the field of precise cardiovascular diagnosis and treatment, thereby becoming a leading force driving industrial development.’”

Mr. Xie Yijing, Managing Director and Head of the Healthcare & Life Sciences Group at China Renaissancestated: “We are honored to have assisted InSight Lifetech in completing this round of private financing. Based on a profound understanding of clinical needs, the InSight Lifetech team has implemented forward-looking strategic layouts, defined products according to international standards, and demonstrated strong commercialization capabilities along with extensive global distribution channels. Within just a few years, its comprehensive, complementary, and highly executable team has established systems for product R&D, manufacturing and quality assurance, and commercialization. We believe that with the continued support of both existing and new shareholders, the company will leverage ‘InSight Efficiency’ to drive advancements in the field of precision cardiovascular intervention, ushering in a new era of precise diagnosis and treatment.”